Bone Biologics (BBLG) vs Curis (CRIS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Curis is the larger company by market cap ($1.7 million vs $1.3 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBLG | CRIS |
|---|---|---|
| Share price | $0.4691 | $0.7094 |
| Market cap | $1.29M | $1.72M |
| 1-day change | -3.77% | -3.69% |
| P/E ratio (TTM) | — | 0.54 |
| EPS (TTM) | $-1.34 | $1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.76 | $33.60 |
| 52-week low | $0.428 | $0.61 |
| Distance from 52-week high | -83.00% | -97.89% |
| Analyst consensus | none | none |
| Avg. price target upside | +2500.72% | +5914.94% |
| Average volume | 378.20K | 199.15K |
| Shares outstanding | 2.76M | 2.43M |
| Employees | 2 | 20 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bone Biologics
BBLG stock →Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration.
Healthcare · Biotechnology · 2 employees
About Curis
CRIS stock →Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.
Healthcare · Biotechnology · 20 employees
BBLG vs CRIS FAQ
Which is bigger, Bone Biologics or Curis?
Curis (CRIS) is larger, with a market capitalization of $1.72M compared with $1.29M for Bone Biologics (BBLG).
Are Bone Biologics and Curis in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.